Feb 13 2025 21 mins 7
CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications.
Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance.
Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation, proliferation and Interferon-γ signature induction.
Visugromab has demonstrated a good safety profile and potent and durable anti-tumor efficacy in combination with anti-PD-1 treatment in advanced cancer patients, as highlighted in its recent Nature publication and interim clinical data.
This week we have a conversation with Eugen Leo, chief medical officer at CatalYm.
01:30-03:38: About CatalYm
03:38-06:59: Solid tumors and also why they are hard to treat
06:59-09:04: Current treatments for solid tumors
09:04-10:47: What is immunotherapy resistance?
10:47-12:23: What is visugromab?
12:23-13:32: CatalYm’s clinical development program
13:32-15:12: What represents success for patients using visugromab?
15:12-17:50: Other treatment options being developed
17:50-19:50: CatalYm’s pipeline and the future
This week’s podcast was sponsored by TCR Solutions.
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
